654073-32-2

Basic information

• Product Name: 1-Azetidinesulfonamide(9CI)
• Synonyms: 1-Azetidinesulfonamide(9CI);azetidine-1-sulfonaMide;1-Azetidinesulfonamide
• CAS NO: 654073-32-2
• Molecular Formula: C₃H₈N₂O₂S
• Molecular Weight: 136.17
• Product Categories: SULFONAMIDE
• Mol File: 654073-32-2.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 276.3±23.0 °C(Predicted)
• Appearance: /
• Density: 1.51±0.1 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Store in freezer, under -20°C
• PKA: 11.52±0.20(Predicted)
• CAS DataBase Reference: 1-Azetidinesulfonamide(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Azetidinesulfonamide(9CI)(654073-32-2)
• EPA Substance Registry System: 1-Azetidinesulfonamide(9CI)(654073-32-2)

Safety Data

• Hazardous Substances Data: 654073-32-2(Hazardous Substances Data)

Usage

General Description

1-Azetidinesulfonamide(9CI) is a chemical compound with the molecular formula C2H6N2O2S. It is a type of sulfonamide with a four-membered heterocyclic ring containing one nitrogen atom and one sulfur atom. 1-Azetidinesulfonamide(9CI) has potential applications in medicinal chemistry, specifically in the development of pharmaceuticals. Sulfonamides are known for their antimicrobial properties and are used as antibiotics and antifungal agents. Additionally, 1-Azetidinesulfonamide(9CI) may also have potential as a building block for the synthesis of other organic compounds. Its specific properties and potential applications may provide value for various industries and research fields.

Upstream product

• 503-29-7 azetidine 
• 96042-30-7 4-(dicyanomethylene)-2-methyl-6-(p-dimethylaminostyryl)-4H-pyran 
• 1271835-78-9 benzyl (azetidin-1-ylsulfonyl)carbamate 

Downstream Products

• 1204707-71-0 N-[2-[(2,3-difluorophenyl)methylsulfanyl]-6-[[(1R,2R)-2,3-dihydroxy-1-methyl-propyl]amino]pyrimidin-4-yl]azetidine-1-sulfonamide 
• 1204707-81-2 N-[2-[(2,3-difluorobenzyl)thio]-6-({(1R)-1-[(4R)-2,2-dimethyl-1,3-dioxolan-4-yl]ethyl}amino)pyrimidin-4-yl]azetidine-1-sulfonamide 
• 1204707-83-4 N-[2-[(2,3-difluorobenzyl)thio]-6-({(1R)-1-[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]ethyl}amino)pyrimidin-4-yl]azetidine-1-sulfonamide 
• 1204707-87-8 (N-[2-[(2,3-difluorobenzyl)thio]-6-({(1S)-1-[(4R)-2,2-dimethyl-1,3-dioxolan-4-yl]ethyl}amino)pyrimidin-4-yl]azetidine-1-sulfonamide) 
• 1204707-89-0 N-[2-[(2,3-difluorobenzyl)thio]-6-({(1S)-1-[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]ethyl}amino)pyrimidin-4-yl]azetidine-1-sulfonamide 
• 1443431-33-1 N-(azetidin-1-ylsulfonyl)-5-chloro-4-{[(5-chloro-6-cyclopropylpyridin-3-yl)oxy]methyl}-2-fluorobenzamide 
• 1443431-23-9 N-(azetidin-1-ylsulfonyl)-4-{[(5-chloro-6-isopropoxypyridin-3-yl)oxy]methyl}-2,5-difluorobenzamide 
• 1446444-51-4 N-(azetidin-1-ylsulfonyl)-5-chloro-4-{[5-chloro-6-(2,2,3,3-tetrafluoropropoxy)pyridin-3-yl]oxy}-2-fluorobenzamide 
• 1446444-52-5 N-(azetidin-1-ylsulfonyl)-5-chloro-4-(3,4-dichlorophenoxy)-2-fluorobenzamide 

Relevant articles and documents

7-(2-anilinopyrimidin-4-yl)-1-benzazepin-2-ones designed by a “cut and glue” strategy are dual aurora a/vegf-r kinase inhibitors

Although overexpression and hyperactivity of protein kinases are causative for a wide range of human cancers, protein kinase inhibitors currently approved as cancer drugs address only a limited number of these enzymes. To identify new chemotypes addressing alternative protein kinases, the basic structure of a known PLK1/VEGF-R2 inhibitor class was formally dissected and reassembled. The resulting 7-(2-anilinopyrimidin-4-yl)-1-benzazepin-2-ones were synthesized and proved to be dual inhibitors of Aurora A kinase and VEGF receptor kinases. Crystal structures of two representatives of the new chemotype in complex with Aurora A showed the ligand orientation in the ATP binding pocket and provided the basis for rational structural modifications. Congeners with attached sulfamide substituents retained Aurora A inhibitory activity. In vitro screening of two members of the new kinase inhibitor family against the cancer cell line panel of the National Cancer Institute (NCI) showed antiproliferative activity in the single-digit micromolar concentration range in the majority of the cell lines.

SULFONAMIDE DERIVATIVES

The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to a new sulfonamide Nav 1

Macrocyclic compounds as inhibitors of viral replication

The embodiments provide compounds of the general formulas I-XIX, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating flaviviral infection, including hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.